首页> 外文OA文献 >Chinese Medicine Shenfu Injection for Heart Failure: A Systematic Review and Meta-Analysis
【2h】

Chinese Medicine Shenfu Injection for Heart Failure: A Systematic Review and Meta-Analysis

机译:中药参附注射液治疗心力衰竭的系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective. Heart failure (HF) is a global public health problem. Early literature studies manifested that Shenfu injection (SFI) is one of the most commonly used traditional Chinese patent medicine for HF in China. This article intended to systematically evaluate the efficacy and safety of SFI for HF. Methods. An extensive search was performed within 6 English and Chinese electronic database up to November 2011. Ninety-nine randomized controlled trails (RCTs) were collected, irrespective of languages. Two authors extracted data and assessed the trial quality independently. RevMan 5.0.2 was used for data analysis. Results. Compared with routine treatment and/or device support, SFI combined with routine treatment and/or device support showed better effect on clinical effect rate, mortality, heart rate, NT-proBNP and 6-minute walk distance. Results in ultrasonic cardiography also showed that SFI combined with routine treatment improved heart function of HF patients. There were no significant difference in blood pressure between SFI and routine treatment groups. Adverse events were reported in thirteen trails with thirteen specific symptoms, while no serious adverse effect was reported. Conclusion. SFI appear to be effective for treating HF. However, further rigorously designed RCTs are warranted because of insufficient methodological rigor in the majority of included trials.
机译:目的。心力衰竭(HF)是全球性的公共卫生问题。早期文献研究表明,神甫注射液(SFI)是中国最常用的心衰中成药之一。本文旨在系统评估SFI对HF的疗效和安全性。方法。截止到2011年11月,在6个中英文电子数据库中进行了广泛的搜索。收集了99种随机对照试验(RCT),与语言无关。两位作者提取了数据并独立评估了试验质量。 RevMan 5.0.2用于数据分析。结果。与常规治疗和/或设备支持相比,SFI结合常规治疗和/或设备支持对临床疗效,死亡率,心率,NT-proBNP和6分钟步行距离显示出更好的效果。超声心动图检查结果还显示,SFI结合常规治疗可改善HF患者的心功能。 SFI组和常规治疗组之间的血压没有显着差异。不良事件有13条,有13种特定症状,但没有严重不良反应的报道。结论。 SFI似乎对治疗HF有效。但是,由于在大多数纳入试验中,方法学上的严谨性不足,因此需要进一步严格设计RCT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号